Int J Cancer by Zhou, Mi et al.
Serum macrophage-derived chemokine/CCL22 levels are 
associated with glioma risk, CD4 T cell lymphopenia and 
survival time
Mi Zhou2, Paige M. Bracci2, Lucie S. McCoy1, George Hsuang1, Joseph L. Wiemels1,2, Terri 
Rice1, Shichun Zheng1, Karl T. Kelsey3, Margaret R. Wrensch1,2, and John K. Wiencke1,2
1Department of Neurological Surgery, School of Medicine, University of California San Francisco, 
San Francisco, CA
2Department of Epidemiology and Biostatistics, University of California San Francisco, San 
Francisco, CA
3Department of Laboratory Medicine and Pathology, Brown University, Providence, RI
Abstract
Defects in antigen presenting cell function have been implicated in glioma immunosuppression. 
We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking 
chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a 
biomarker of glioma risk, survival, and immune dysfunction. Cluster models were used to 
examine the relationship between CCL22 and glioma risk. Patient survival was assessed using 
Cox regression models. We also examined the relationship between CCL22 levels and CD4 cell 
counts, as well as allergy history and IgE levels. CCL22 levels were significantly lower among 
glioma cases compared to controls (Mean±SEM: 1.23±0.03 ng/mL in cases versus 1.60±0.03 
ng/mL in controls, P<0.0001), and this difference remained significant even after controlling for 
other covariates in the cluster models (highest quartile versus lowest Odds Ratio=0.21, P<0.0001). 
CD4 cell counts were positively correlated with CCL22 in glioma cases (Spearman r2=0.51, 
P<0.01) and were significantly lower in cases compared with controls. Higher CCL22 levels were 
associated with longer survival in all cases combined and in GBM cases (hazard ratioallcases=0.81; 
95% CI: 0.72–0.91, P=0.0003). CCL22 levels were not associated with IgE level or self-reported 
allergies. Circulating CCL22 levels are related to both glioma risk and survival duration 
independent of age, histology, grade and IDH mutation status. CCL22 should be considered a 
marker of immune status with potential prognostic value.
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Gliomas are the most common form of primary brain tumor with an incidence rate of 
approximately 6.5 individuals diagnosed per 100,000 in the United States1. Traditional 
histopathological criteria, age, and some tumor markers are currently used to assess glioma 
patient prognosis2, 38, 9. Survival for patients diagnosed with glioblastomas (World Health 
Organization (WHO) grade IV) is poor with a median survival of 14.6 months4. The median 
survival of grade III astrocytoma patients is in the range of 2 to 3 years while those with 
grade III oligodendrogliomas have a median survival of 3 to 6 years4. Patients who are 
younger at diagnosis and who have IDH mutated tumors also have a more favorable 
survival4. The standard therapies for high grade glioma, including surgery, temozolomide 
(TMZ) chemotherapy and radiation, have been shown to improve survival, although 
modestly4. Important molecular subsets of glioma also are associated with heritable risk5–7. 
It has also been recognized for many years that glioma patients, particularly GBM patients, 
show peripheral immune defects affecting T cells10, 11. Lymphocyte counts (particularly 
CD4 cells) in glioma patients are reduced and T-cell function is also suppressed, with 
impaired proliferation in response to IL2 and nonspecific mitogens12. A study of patients 
with high-grade gliomas (grades III and IV) treated with radiation and TMZ showed that 
after 2 months of treatment about 40% of patients had CD4 blood counts less than 200 
cells/µL13. These patients continued to have low CD4 counts for the full year of follow-up 
and exhibited early mortality from tumor progression13. Other studies also have reported 
that low CD4 counts were associated with poorer glioma survival times14, 15. More 
generally, CD4 lymphopenia has been shown to be a grave prognostic indicator in multiple 
types of cancers16–21. Although the etiology of depressed T cell immunity in glioma is 
complex; exposures to therapeutic steroids, chemotherapy and ionizing radiation as well as 
tumor generated immune suppression are thought to be involved12, 13. One important aspect 
of glioma related suppression of the immune response is the effect that tumors may have on 
professional antigen presenting cells (APC) and their crosstalk with T cells15, 22, 23. For 
example, circulating peripheral blood monocytes in patients with GBM have increased 
expression of the suppressive B7-H1 protein and promote T cell apoptosis24; this 
suppressive phenotype was induced by exposing monocytes to glioma cell lines and 
supernatants. Glioma cells exposed to direct contact with blood monocytes were shown in 
an earlier study to induce a suppressive phenotype25. A crucial link between macrophage/
dendritic cells (DC) and T cell immunity is the macrophage-derived chemokine CCL2226. 
CCL22 is a CC type chemokine and a potent chemoattractant for CD4 and CD8 T cells, as 
well as for DCs expressing the CCL22 receptor CCR4. It is involved in chronic 
inflammation mediated by the continuous homing of DCs and lymphocytes27, 28. In this 
study, we hypothesized that the chemokine CCL22 may be a biomarker of macrophage/DC 
compartment of immune suppression and provide relevant information about anti-tumor 
responses elicited by the host that may be negatively impacted by tumor cells or 
immunosuppressive treatments. We show that reduced levels of serum CCL22 are common 
in glioma patients and associated with low CD4 cell counts and shorter survival times. This 
suggests CCL22 may be a useful marker of a suppressed immune function.
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Study participants and interview
All cases were adults with newly diagnosed histologically confirmed glioma (International 
Classification of Disease for Oncology, morphology codes 9380–9481). Population-based 
cases residing in the six Bay Area counties were ascertained using the Cancer Prevention 
Institute of California’s early case ascertainment system during three recruitment periods: 
May 1997 to August 1999, November 2001 to September 2005, and September 2006 to 
September 2009. Clinic-based cases diagnosed between 2002–2006, 2006–2010, and 2009–
2012 were recruited from the UCSF Neuro-oncology Clinic, regardless of place of 
residence. Cases enrolled in the 2009–2012 clinic-based recruitment were eligible to 
participate if they were 18 years or older at diagnosis, and cases recruited in the earlier years 
of the study were eligible to participate if they were 20 years and older at diagnosis.
Population-based controls from the same residential area as the population-based cases were 
identified using random digit dialing and were frequency matched to population-based cases 
on age group, gender and ethnicity. Clinic-based controls age 18 years and older were 
recruited from the UCSF phlebotomy clinic between 2010–2012 and frequency matched to 
clinic-based cases on age group, gender and ethnicity. Informed consent was obtained from 
all study participants and study methods were approved by the Committee on Human 
Research at the University of California, San Francisco.
Pathological material was retrieved, when possible, for all resected brain cancers and 
reviewed and classified by one of two neuropathologists (Kenneth Aldape, MD Anderson, 
Houston, TX and Tarik Tihan, UCSF, San Francisco, CA). Blood and serum samples were 
usually collected at the time of interview. Allergy history data were collected in tabular form 
as described in detail in our earlier report37, 38. All participants who provided a blood 
sample were administered an additional questionnaire at the time of blood draw about 
current and recent medications and treatments. IDH mutation was measured in cases with 
tumor tissue available as previously described9.
Measurement of serum CCL22 levels
The Luminex assay was developed using a standard sandwich capture format. Capture 
antibody to human CCL22 (DY336, Part 840498, R&D system, Minneapolis) was coupled 
to magnetic Luminex microspheres by using a two-step carbodiimide reaction. Serum 
samples were diluted 1:100 in sample diluent, which was a mixture of PBS, 10% (vol/vol) 
fetal bovine serum, and 2.5% (vol/vol) CBS-K (Millipore Corporation, Hayward, CA). The 
solution was then incubated at room temperature for 1 hour on a shaker. A standard curve 
was created by diluting human CCL22 (DY336, Part 840500, R&D system, Minneapolis) 
using the same sample diluent. The CCL22 standards or participant serum samples and 
coupled CCL22 microspheres were then incubated for 2 hours at room temperature on a 
shaker using a 96-well flat bottom plate (Bio-Rad Laboratories, Inc., Hercules, CA) and 
subsequently washed with the wash buffer (Bio-Rad Laboratories, Inc.). This step was 
followed by the addition of 25 µL of 1:200 diluted (45ng/mL) biotinylated anti-human 
CCL22 antibody (DY336, Part 840499, R&D system, Minneapolis) to each well and the 
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incubation of the mixture at room temperature for 30 minutes on a shaker. The solution was 
then washed and treated with 50 µL of streptavidin-conjugated R-phycoerythrin 1:100 
diluted stock (Bio-Rad Laboratories, Inc.). After a 10 minutes incubation and final wash, the 
microspheres were resuspended in 105 µL of assay buffer (Bio-Rad Laboratories, Inc.). The 
amount of CCL22 bound to the microspheres by this antibody sandwich technique was 
determined by the median fluorescence intensity (MFI) of the reporter molecules, 
phycoerythrin, using the Bio-plex 200 plate reader system. The MFI of the unknown serum 
sample was then converted into a picograms-per-milliliter value based on the known 
concentrations of the standard curve by using a five-parameter (5PL) regression formula. 
Each sample was run with a replicate. A single serum sample from a person without a brain 
tumor was repeated on some of the assay plates (13 out of 24). We performed standard 
addition experiments that yielded a recovery rate of 80%.
Flourescence-activated cell sorting (FACS) analysis of CD4 cells levels and IgE analysis
We measured CD4 cell levels on 47 clinic-based cases and 146 clinic-based controls 
recruited from the 2009–2012 clinic-based series of the study. The blood samples were 
directly stained with anti-human CD4 APC antibody (eBioscience, San Diego, cat 
#17-0048-41), anti-human CD45 PerCP-Cy5.5 antibody (eBioscience, San Diego, cat 
#45-0459-41), and anti-human CD3 FITC antibody (eBioscience, San Diego, cat 
#11-0038-41). CD45 and CD3 were added to provide reference for CD4 values. After 
staining the blood was incubated for 20 minutes in the dark at 4°C. Cal-Lyse Solution 
(Invitrogen, Camarillo, cat #GAS-010) was then added to lyse red blood cells and fix the 
cells. Flow cytometry counting beads were added for absolute quantification of CD4 cells. 
Flow cytometry was performed within 48 hours of blood draw on the FACSCalibur (Becton 
Dickinson, San Jose) flow cytometer using Cell-Quest (Becton Dickinson, San Jose) 
software. Analysis of flow data was done using Flowjo software (TreeStar Inc, Ashland).
IgE levels were assessed using Pharmacia Diagnostics UniCAP fluorescent “sandwich” 
assay as described previously29. IgE levels were determined using serum derived from the 
same blood draw as used for the CCL22 analysis. Total IgE was determined by measuring 
fluorescence against the standard curve with known quantity inputs as previously 
described30.
Statistical methods
Statistical analyses were conducted using SAS v9.3 (SAS Institute, Cary NC). Odds ratios 
for glioma cases versus controls were computed using a multivariable cluster analysis model 
(Proc Genmod) which controlled for variation within the CCL22 batches. Models were 
adjusted for age, gender, ethnicity (white/nonwhite), education (college education yes/no) 
and smoking history (ever/never). Analyses were conducted separately for all gliomas and 
by histological subtype (GBM versus non-GBM). For the case/control comparisons, CCL22 
values were categorized into quartiles based on the distribution among controls. Total IgE 
was analyzed both as a log-transformed continuous variable and for comparison with earlier 
studies, as a categorical variable with groups defined based on clinically relevant cut points 
(IgE > 100 kU/ L = “elevated”, 25–100 kU/L = “borderline” and < 25 kU/L = “normal”). 
Cox proportional hazard models were run to evaluate the association between CCL22 levels 
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and survival in glioma cases. Survival models controlled for age at diagnosis, race (white/
non-white), gender, smoking history (ever/never), college degree, number of days between 
diagnosis and blood draw (continuous), Dexamethasone use at blood draw, and first course 
of treatment (Temozolomide or other chemotherapy use, radiation, and extent of surgery 
(biopsy only vs. any resection)). Survival was measured by calculating the total number of 
days between the date of diagnosis and date of death (if deceased) or last follow-up (if alive 
or lost to follow-up). Cases who were alive at the last follow-up or were lost to follow-up 
were treated as censored in the analysis. For the survival models, we compared the upper 
three quartiles of CCL22 to the lowest quartile since the survival experience for cases in the 
upper three quartiles was very similar (Supplemental Figure 1).
Results
Our study consisted of 1208 newly diagnosed glioma cases and 976 controls; cases and 
controls were comparable in their ethnicity and level of education (Table 1). However, cases 
were more likely than controls to be male, non-smokers, and less likely to report a history of 
allergies. Cases were also younger on average (median=51 years old) than controls 
(median=56 years old). Glioblastomas (GBM) were the most common histological subtype 
of brain tumor, followed by anaplastic astrocytomas, grade 2 astrocytomas, and 
oligodendrogliomas. More than three quarters of GBM cases (>82%) received the current 
standard of care treatment as a first course of treatment, which includes TMZ, radiation, and 
resection. Among GBM patients, 7% had IDH mutant tumors whereas for non-GBM 
patients, 74% of tumors were IDH mutant (Supplemental Table 1).
Serum CCL22 levels are depressed in glioma cases compared to controls
The overall concentration of CCL22 was statistically significantly lower in glioma cases 
compared to controls (mean±SEM: 1.23±0.03 ng/mL versus 1.60±0.03 ng/mL respectively, 
P<0.0001, Table 2). The results from the cluster models showed that after controlling for 
covariates, CCL22 levels were statistically significantly lower in cases than controls (highest 
versus lowest quartile OR: 0.21, 95% CI: 0.14–0.30, P<0.0001). Results were consistent for 
both GBM and non-GBM cases, but the magnitude of the effect was greater for GBM cases. 
In particular, for GBM cases versus controls, the OR for the highest versus lowest quartile 
was 0.16 (95% CI=0.10–0.24, p<0.0001); while in the non-GBM comparison it was 0.30 
(95% CI=0.20–0.41, p<0.001) (Table 2). However, further analyses among only the non-
GBM cases revealed that the lowest CCL22 values were among the grade III astrocytomas. 
No overall difference in CCL22 concentrations was noted among grade II 
oligodendroglioma or oligoastrocytoma cases compared to controls (Supplemental Table 1).
Low CCL22 levels are associated with shorter survival
We found that lower CCL22 levels were associated with shorter median survival days 
among all cases (Table 3). Cox regression models using continuous log transformed CCL22 
values showed a significantly lower risk of death as CCL22 levels increased in all cases as 
well as in the GBM only case group (HRallcases=0.81; 95% CI: 0.72–0.91, P<0.001) (Table 
3). Cox regression models comparing the upper three quartiles of CCL22 to the lowest 
quartile in all cases also showed a significantly lower risk of death in cases with higher 
Zhou et al. Page 5













CCL22 levels (highest quartiles vs. lowest quartile HRallcases=0.80; 95% CI:0.69–0.93, 
P=0.003). However, the highest quartiles versus lowest quartile comparison did not show 
statistical significance in models where GBM and non-GBM cases were run separately. The 
Kaplan Meier (KM) curves comparing the survival of cases in the upper three quartiles (Q2–
Q4) of CCL22 to those in the lowest quartile (Q1) are shown in Figure 1. The KM curves 
show that survival in the Q2–Q4 group (with higher CCL22 levels) is better than that in the 
Q1 group (with lower CCL22 levels) for all cases as well as the GBM and non-GBM case 
groups (Figure 1: A, B, and C).
We found that in GBM cases, the CCL22 levels were higher in cases treated with radiation 
before blood draw (p=0.04), but we did not find any significant differences in CCL22 levels 
when comparing cases who took chemotherapy prior to blood draw to those who did not 
(Supplemental Table 6). However, cases taking dexamethasone use at blood draw had 
significantly lower CCL22 levels than cases not taking dexamethasone at the time of blood 
draw. Dexamethasone use, along with first course of treatment, demographic, and other 
factors were adjusted for in the Cox regression models that show an association between 
CCL22 levels and overall survival in GBMs.
Serum CCL22 levels are associated with CD3 and CD4 cells in glioma cases
For the 47 cases and 146 controls with FACS analysis data, we compared the CCL22 levels 
with CD3 (pan-T cell marker), CD4 and CD45 cell counts as well as the ratio of CD3/CD45 
and CD4/CD45. There were no observed differences in total CD45 cells (total leukocytes) 
among cases and controls. However, we observed a significant positive correlation between 
CCL22 levels and both CD3 and CD4 counts in cases (Table 4). The correlations between 
CCL22 and CD3 and CD4 were stronger in cases than in controls (p<0.01 in cases and 
p>=0.10 in controls for both CD3 and CD4). The mean absolute CD4 cell counts in glioma 
cases also were markedly lower than that in controls (659 cells/µL in all cases and 392 in 
GBM cases versus 813 in controls, p=0.04). Statistically significant case/control differences 
were also observed for the ratios of CD3/CD45 and CD4/CD45, with cases having lower 
ratios (p<0.01 for each).
When we grouped the CD4 counts into three clinically meaningful categories (<200, 200–
499, 500+ CD4 cells/µL), we found that in cases, the mean value of CCL22 increased as 
CD4 levels increased (Figure 2). Cases with the lowest levels of CD4 cells (<200) had a 
mean serum CCL22 level of 0.57 ng/mL, whereas cases with CD4 counts >=500 had a mean 
CCL22 level of 1.20 ng/mL (p=0.002 for difference in means between the CD4 groups). 
However, we did not observe differences in CCL22 levels among the three CD4 groups in 
controls (p=0.65 for difference in mean CCL22 levels across the CD4 groups). In addition, 
we found that the CD4 counts of cases recently treated with radiation or chemotherapy were 
significantly lower than cases who had not yet received treatment (P<0.001, Supplementary 
Table 4b).
CCL22 and Allergies/IgE
We also examined whether CCL22 levels were associated with reported allergy history or 
measured serum IgE levels. Null relationships were observed between CCL22 concentration 
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and any reported allergy, total number of allergies reported, or IgE measurements in both 
cases and controls.
Discussion
Although systemic defects in APC function have been observed in glioma patients15, 22, 23, 
there are no established biomarkers for assessing this dimension of the immune response for 
clinical prognostication. Here we focused on serum CCL22 as a simple protein assay 
applicable to routinely collected blood sera. A strong rationale for considering CCL22 as a 
biomarker of APC function is that DCs and monocyte derived macrophages are the most 
potent producers of CCL22 in vitro and in vivo31. The maturation of monocyte precursors 
into DCs with a functional APC phenotype leads to a many-fold increased expression and 
secretion of CCL2231. Given our current observation of suppressed CCL22 levels in glioma 
patients and its association with CD4 lymphopenia, it is reasonable to propose that this 
reflects depressed DC function and T cell trafficking.
We did not find a significant association between chemotherapy taken before blood draw 
and CCL22 levels, but found that GBM cases who had radiation before blood draw had 
higher CCL22 levels than those who had not yet had radiation. We explored the time 
elapsed since the last dose of radiation or chemotherapy and the day of the blood draw but 
found no correlation between time since last dose of either radiation or chemotherapy and 
CCL22 concentrations. Medications such as dexamethasone may also influence CCL22 
expression32, 33 and in our data current dexamethasone exposure was associated with 
significantly lower CCL22 levels among glioma cases.
We found a strong correlation between CCL22 values and CD4 counts in cases. We also 
found that cases who received chemotherapy or radiation before blood draw had 
significantly lower CD4 counts than cases who had not yet received these treatments. 
Prospective studies during TMZ and radiation therapy indicate an inhibitory effect on CD4 
and B cells followed by a recovery phase in some but not all exposed patients. Prolonged 
lymphopenia has been associated with the patient’s ability to generate appropriate cytokine 
responses including the production of IL7 and IL1534. Perhaps chemokine directed cell 
trafficking as marked by CCL22 also fails to recover in some patients and could explain our 
observed CD4 lymphopenia. It is interesting that another CCR4 responsive chemokine, 
CCL2, was found to be depressed in sera of GBM patients along with CD4 cells, and both 
appeared to correlate with increases in a CD14+ HLA-DR- subtype of blood monocyte35. 
Our earlier study showed there were similar percentages of cases and controls positive for 
antibodies to three herpes viruses (herpes simplex virus, cytomegalovirus, and Epstein-Barr 
virus)36. In addition, circulating CD14 levels in our past study37 were significantly higher in 
cases compared with controls. Furthermore, in our current study we did not observe 
decreased total leukocyte counts in glioma cases versus controls. These observations argue 
against the hypothesis that lower CCL22 levels in glioma patients might be primarily the 
result of nonspecific effects of advanced tumors or therapies. Taken together, these 
observations implicate monocyte and DC derived trafficking molecules with suppression of 
T cell immunity. Further study is required to identify whether suppression of CCL22 is an 
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intrinsic patient related defect, or a tumor driven effect or some combinations of all these 
possibilities.
IDH mutation, 1p19q codeletion, and MGMT methylation are tumor markers that have been 
shown to be associated with improved prognosis in glioma patients50. We controlled for the 
effect of IDH mutation in most patients and 1p19q codeletion in patients with 
oligodendroglial tumors, but were not able to examine MGMT methylation. However, 
MGMT methylation is highly correlated with IDH status and we have IDH mutation results 
for most cases.
The present study is, to our knowledge, the first to assess the relationship of peripheral 
CCL22 levels in glioma survival, which can be more easily applied as a routine assay for 
prognosis than most tumor markers. Our findings are consistent with two cohort studies on 
metastatic breast cancer showing that low CCL22 levels were associated both with low CD4 
counts and reduced overall survival16. This raises the possibility that in the context of radio-
chemotherapy for cancer, CCL22 might be considered an indicator of DC related immune 
suppression. However, the association of low CCL22 and abnormal CD4 counts was not 
observed in our control group, even though a small number of subjects demonstrated <200 
CD4 cells/µL. In these exceptional control patients, a history of HIV, hepatitis or 
autoimmune disorders were common though their CCL22 values were normal. The 
specificity of chemokine measurements as indicators of DC function in different clinical 
populations requires further study.
Abnormalities in T cell immunity are most extreme in high grade (grades III and IV) glioma 
compared with lower grades. Our observations parallel this grade dependence in the sense 
that CCL22 concentrations were not significantly depressed in grade II glioma irrespective 
of histological subtype. There were individual exceptions, however, with some grade II 
patients demonstrating very low CCL22 and CD4 counts. The survival curve among non-
GBM patients demonstrated a survival advantage among patients with higher CCL22 levels 
although the sample size of non-GBM cases was limited. Tumor grade and histology 
subtype analyses revealed that patients with grade III astrocytoma had the lowest CCL22 
concentrations compared to those with the grade II oligodendroglioma, grade II astrocytoma, 
and oligoastrocytoma. Further work will be necessary to assess whether specific 
morphologies drive the survival associations in non-GBM patients and whether CCL22 may 
be useful in identifying lower grade glioma patients at high risk for early progression.
We, and others, have shown that T helper 2 (a subset of CD4 cells) related phenotypes such 
as atopic allergy are underrepresented in glioma patients38, 39. Atopic conditions have been 
linked to CCL2240. One study41 showed that increased cord blood CCL22 levels were 
associated with development of allergic sensitization and asthma; CCL22 increases preceded 
allergy development during the first 6 years of life. Another group demonstrated that cord 
blood CCL22 levels were associated with elevated total IgE levels during preschool age42. 
Our analyses did not reveal any associations of allergy history or serum IgE concentrations 
with CCL22 among cases or controls. Previous reports linking serum CCL22 with atopic 
conditions concerned children and it is not known whether circulating levels in adulthood 
are expected to signal greater atopic risk. It is also possible that the repertoire of cells 
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responsive to CCL22 is broader than just CD4 Th2 cells. Targeted knock down of CCL22 in 
DCs affected CD8 cytotoxic cells as well as CD4 and CD25+ Foxp3+ regulatory cells43. 
Finally, a limitation of our studies in cases is that serum samples were obtained after glioma 
diagnosis and it would be very interesting to know if CCL22 depression precedes diagnosis 
and may therefore reflect a preexisting alteration in macrophage/DC function.
Our study focused on a peripheral marker of immune suppression and we did not evaluate 
the potential relationship between serum CCL22 and production of this chemokine by the 
tumor. CCL22 and CCL2 are implicated in the trafficking of T cells including T regs into 
the tumor microenvironment44. IFN-γ, IL1β and TNF-α will favor CCL22 overproduction 
by tumor cells, which promotes the recruitment of CCR4+ blood T reg that favors the 
development of a tolerogenic environment45. Trafficking and accumulation of T regs at the 
tumor site may have a negative effect on patient survival46. However, not all studies support 
this view47 and the issue is complicated by the strong correlation of immune infiltrates with 
WHO glioma grade. In any case, it is not clear what effect local tumor related production of 
CCL22 would have on the peripheral blood concentration. Both CCL22 and CCL2, the 
primary chemokines directing T regs, are markedly depressed in sera of glioma patients, at 
least following tumor resection. It will be necessary to characterize the T cell infiltrate in 
glioma tissues and assess the peripheral chemokine profile in the same patients to address 
whether the blood parameter reflects the T cell immune response of the tumor 
microenvironment48.
In conclusion, our observations combined with previous work suggest that monocyte and 
DC produced CCL22 and, possibly, CCL2 may serve as markers in glioma patients that 
signal patients at risk of prolonged CD4 cell suppression and poorer survival. New strategies 
to augment antitumor immunity49 can be adversely affected by persistent defects in APC 
cells and CCL22 may prove a useful marker to assess APC function in patients receiving 
immunotherapy.
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Description of the novelty and impact of the work
Here, we present the novel observation that depressed levels of CCL22 are common in 
glioma patients. We further have found that these depressed CCL22 levels are associated 
with low CD4 cell counts and poorer survival times. Thus, CCL22 could be a useful 
biomarker reflecting the suppressed immunity of glioma patients. It may also serve as a 
significant prognostic factor of gliomas and a possible marker of cancer associated 
suppression of immune function.
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Kaplan-Meier survival curves stratified by CCL22 levels (Quartile 1 vs. Quartiles 2–4) in all 
glioma cases (a); GBM cases (b) and non-GBM cases (c), UCSF Adult Glioma Study 1997–
2012.
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CCL22 levels by case/control status within CD4 groupings. Samples were divided into three 
groups according to CD4 counts/µL (<200, 200–499, >=500), CCL22 levels (ng/mL) were 
compared in cases and controls of each group, UCSF Adult Glioma Study 2010–2012. 
[Color figure can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
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